Lara Meisner Biography and Net Worth

Insider of Viridian Therapeutics

Lara Meisner joins Bicara with more than two decades of experience in providing counsel to public and private companies across key legal and operational functions. Prior to Bicara, Lara served as the Chief Legal Officer, Compliance Officer, and Corporate Secretary at Viridian Therapeutics, where as part of the executive team, she led all aspects of legal and compliance. Prior to that, Lara served as Vice President of Legal at Astria Therapeutics, Inc. and as Senior Corporate Counsel at Verastem Oncology. She has also held a variety of in-house legal positions in both public and private technology companies.

Lara received a JD from Temple University Beasley School of Law and a Bachelor of Arts degree from the University of Michigan.

What is Lara Meisner's net worth?: The estimated net worth of Lara Meisner is at least $432,781.24 as of June 15th, 2023. Meisner owns 29,971 shares of Viridian Therapeutics stock worth more than $432,781 as of March 31st. This net worth evaluation does not reflect any other investments that Meisner may own. Learn More about Lara Meisner's net worth.
How do I contact Lara Meisner?: The corporate mailing address for Meisner and other Viridian Therapeutics executives is 6200 LOOKOUT ROAD, BOULDER CO, 80301. Viridian Therapeutics can also be reached via phone at (617) 272-4600 and via email at daniel@lifesciadvisors.com. Learn More on Lara Meisner's contact information.
Has Lara Meisner been buying or selling shares of Viridian Therapeutics?: Lara Meisner has not been actively trading shares of Viridian Therapeutics during the past quarter. Most recently, Lara Meisner sold 2,269 shares of the business's stock in a transaction on Thursday, June 15th. The shares were sold at an average price of $28.02, for a transaction totalling $63,577.38. Following the completion of the sale, the insider now directly owns 29,971 shares of the company's stock, valued at $839,787.42. Learn More on Lara Meisner's trading history.
Who are Viridian Therapeutics' active insiders?: Viridian Therapeutics' insider roster includes Kristian Humer (CFO), Stephen Mahoney (President and Chief Executive Officer), Lara Meisner (Insider), and Jonathan Violin (Insider). Learn More on Viridian Therapeutics' active insiders.
Are insiders buying or selling shares of Viridian Therapeutics?: During the last twelve months, Viridian Therapeutics insiders bought shares 3 times. They purchased a total of 1,626,400 shares worth more than $30,616,312.00. The most recent insider tranaction occured on September, 27th when COO Thomas W Beetham bought 5,000 shares worth more than $117,050.00. Insiders at Viridian Therapeutics own 0.7% of the company. Learn More about insider trades at Viridian Therapeutics.
Information on this page was last updated on 9/27/2024.

Lara Meisner Insider Trading History at Viridian Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/15/2023	Sell	2,269	$28.02	$63,577.38	29,971
6/5/2023	Sell	499	$25.03	$12,489.97	29,971
6/2/2023	Sell	1,875	$24.21	$45,393.75	29,971
3/9/2023	Sell	29,971	$29.07	$871,256.97
1/23/2023	Sell	6,843	$35.66	$244,021.38
12/20/2022	Sell	600	$28.07	$16,842.00
12/16/2022	Sell	1,297	$28.44	$36,886.68
12/14/2022	Sell	15,656	$28.12	$440,246.72
12/12/2022	Sell	600	$28.05	$16,830.00
11/15/2022	Sell	8,125	$22.05	$179,156.25

Lara Meisner Buying and Selling Activity at Viridian Therapeutics

Viridian Therapeutics Company Overview

Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.

Today's Range

Now: $14.44

$14.19

$14.74

50 Day Range

MA: $16.75

$14.16

$20.08

2 Week Range

Now: $14.44

$11.40

$27.20

Volume

594,046 shs

Average Volume

1,172,191 shs

Market Capitalization

$1.18 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.05